Trials / Completed
CompletedNCT06408285
A Study of TQC3927 Powder for Inhalation in Healthy Adult Subjects
A Phase I Clinical Study on the Safety, Tolerance and Pharmacokinetic Characteristics of Single Dose Escalation of TQC3927 Powder for Inhalation in Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This is a dose escalation trial. The dosing regimen involves a single-dose study. This is a single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetic characteristics of TQC3927 powder for inhalation in healthy adults subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQC3927 powder for inhalation | TQC3927 is a targeted inhibitor. |
| DRUG | TQC3927 powder for inhalation placebo | TQC3927 powder for inhalation placebo contains no active substance. |
Timeline
- Start date
- 2024-05-22
- Primary completion
- 2024-08-19
- Completion
- 2024-08-19
- First posted
- 2024-05-10
- Last updated
- 2024-10-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06408285. Inclusion in this directory is not an endorsement.